search
Back to results

The First Therapeutic Intervention in Malignant Pleural Effusion Trial (TIME-1)

Primary Purpose

Malignant Pleural Effusion, Pleural Effusion

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Large bore chest drain + NSAID based analgesic regimen
Small bore chest drain + NSAID based analgesic regimen
Large bore chest drain + opiate based analgesic regimen
Small bore chest drain + opiate based analgesic regimen
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Malignant Pleural Effusion focused on measuring Pleural malignancy, pleural effusion, pleurodesis, chest tube, cancer, cancer pain management

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Clinically confident diagnosis of malignant pleural effusion requiring pleurodesis. The diagnosis may be established by one of:

    • Histologically proven pleural malignancy OR
    • Typical features of pleural malignancy seen on direct vision during thoracoscopy OR
    • Pleural effusion in the context of histologically proven cancer elsewhere
  2. Expected survival more than 1 month
  3. Written informed consent

Exclusion Criteria:

  1. Age < 18 years
  2. Primary lymphoma or small cell lung carcinoma
  3. Patients who are pregnant or lactating
  4. Inability to give informed consent
  5. History of GI bleeding or of untreated peptic ulceration
  6. Known sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)/opiates/acetaminophen
  7. Hypercapnic respiratory failure
  8. Known intravenous drug abuse
  9. Severe renal or liver disease
  10. Known bleeding diathesis
  11. Warfarin therapy
  12. Current or recent (within 2 weeks) corticosteroid steroid therapy

Sites / Locations

  • UC Davis Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

1

2

3

4

Arm Description

Outcomes

Primary Outcome Measures

An average pain score over 72 hours post pleurodesis for malignant pleural effusion
Pleurodesis success at 3 months post randomization (time to relapse of pleural effusion)

Secondary Outcome Measures

Presence of chronic chest pain on the side of the pleurodesis
Presence of chronic chest pain on the side of the pleurodesis

Full Information

First Posted
May 7, 2009
Last Updated
July 16, 2015
Sponsor
University of California, Davis
search

1. Study Identification

Unique Protocol Identification Number
NCT00896285
Brief Title
The First Therapeutic Intervention in Malignant Pleural Effusion Trial
Acronym
TIME-1
Official Title
TIME1: A 2 X 2 Factorial Trial to Assess Whether Non-steroidal Anti-inflammatory Analgesics and Small-bore Chest Tubes Are Less Painful Than Opiate Analgesics and Large-bore Chest Tubes in Pleurodesis for Malignant Pleural Effusion.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, Davis

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Fluid caused by cancer cells may accumulate in the lining of the lung. Draining the fluid with a chest tube may relieve pain and shortness of breath. To stop the fluid from coming back again, patients are given a medicine (talc) into the chest drain to seal up the space around the lung. This procedure is known as pleurodesis. This sometimes causes pain and discomfort, and the investigators do not know the best way of preventing this. The investigators hope to find the best way to prevent pain during pleurodesis.
Detailed Description
Patients with metastatic cancer often have fluid collecting around the lung as a result of cancer cells spreading to the membranes adjacent to the lung (malignant pleural effusion). The standard way of treating this condition, which may cause unpleasant symptoms such as breathlessness and cough, is to drain the fluid off and then seal the cavity, using a drug (talc) given into the chest drain. Talc causes inflammation in the lining of the lung and chest wall, sticking the two surfaces together and preventing fluid from recurring. This procedure is often very painful; the pain may be partly related to the size of the chest tube used and the type of analgesia taken by the patient during the procedure. Reducing the amount of pain associated with this procedure would be a substantial benefit for patients undergoing this procedure. This trial is looking at which of two different drug regimens is more effective in preventing pleurodesis pain, and whether the size of chest tube influences pain. It will also address whether either of these influences success rate of pleurodesis. We hope to learn whether the size of chest drain or the type of pain medication given (ibuprofen or morphine) influences the amount of pain felt after the pleurodesis procedure. We hope to find the best way of preventing pain during this procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malignant Pleural Effusion, Pleural Effusion
Keywords
Pleural malignancy, pleural effusion, pleurodesis, chest tube, cancer, cancer pain management

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Active Comparator
Arm Title
3
Arm Type
Active Comparator
Arm Title
4
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
Large bore chest drain + NSAID based analgesic regimen
Intervention Description
Chest tube greater than 14 French size and ibuprofen.
Intervention Type
Other
Intervention Name(s)
Small bore chest drain + NSAID based analgesic regimen
Intervention Description
Chest tube less than or equal to 14 French size and ibuprofen.
Intervention Type
Other
Intervention Name(s)
Large bore chest drain + opiate based analgesic regimen
Intervention Description
Chest tube greater than 14 French size and morphine.
Intervention Type
Other
Intervention Name(s)
Small bore chest drain + opiate based analgesic regimen
Intervention Description
Chest tube less than or equal to 14 French size and morphine.
Primary Outcome Measure Information:
Title
An average pain score over 72 hours post pleurodesis for malignant pleural effusion
Time Frame
72 hours
Title
Pleurodesis success at 3 months post randomization (time to relapse of pleural effusion)
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Presence of chronic chest pain on the side of the pleurodesis
Time Frame
6 weeks
Title
Presence of chronic chest pain on the side of the pleurodesis
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinically confident diagnosis of malignant pleural effusion requiring pleurodesis. The diagnosis may be established by one of: Histologically proven pleural malignancy OR Typical features of pleural malignancy seen on direct vision during thoracoscopy OR Pleural effusion in the context of histologically proven cancer elsewhere Expected survival more than 1 month Written informed consent Exclusion Criteria: Age < 18 years Primary lymphoma or small cell lung carcinoma Patients who are pregnant or lactating Inability to give informed consent History of GI bleeding or of untreated peptic ulceration Known sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)/opiates/acetaminophen Hypercapnic respiratory failure Known intravenous drug abuse Severe renal or liver disease Known bleeding diathesis Warfarin therapy Current or recent (within 2 weeks) corticosteroid steroid therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
RJO Davies, Dr.
Organizational Affiliation
Oxford Pleural Unit, Churchill Hospital, Oxford, England
Official's Role
Principal Investigator
Facility Information:
Facility Name
UC Davis Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States

12. IPD Sharing Statement

Learn more about this trial

The First Therapeutic Intervention in Malignant Pleural Effusion Trial

We'll reach out to this number within 24 hrs